The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which bring fear to the patients，especially for those who cannot tolerate or refuse chemotherapy.Several studies indicated that the strategies of chemo-free ,such as the combination of immunotherapy with antiangiogenic therapy or with SBRT, were safe and well tolerated, without increasing adverse reactions. Both of them have a promising efficacy with a manageable toxicity profile in patients with resectable NSCLC. The investigators aim to assess the activity and safety of neoadjuvant SBRT and immunotherapy plus antiangiogenic therapy in patients with resectable NSCLC.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
39
SBRT 8Gy\*3
Tislelizumab (immunotherapy) 200mg Q3W
Anlotinib 8mg D1-D14 Q3W
Pathologic Complete Response(pCR, rate)
Time frame: At the time of surgery
Major pathologic response rate(MPR rate)，Disease-free survival（DFS, month），Event-free survival（EFS,month）
Time frame: Major Pathologic Response (MPR, rate ):At the time of surgery Disease-Free Survival（DFS, month):From enrollment to disease recurrence or death from any cause Event-Free Survival（EFS,month）：From enrollment to the first pre-specified event
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.